◆ mixed
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the US since September 30, 2026. A supplemental NDA (sNDA) for the PIK3CA mutant indication was submitted August 26, 2026; no PDUFA goal date has been publicly confirmed yet.
REVTORPYK gedatolisib Updated Nov 9
What to watch
Watch for the FDA's acceptance and PDUFA goal date for the sNDA covering the PIK3CA mutant indication, which would be the next major regulatory catalyst. Also monitor Q4 2026 earnings (expected early 2027) for the first meaningful product revenue figures and prescription trends. The stock's 126.5% implied upside to the mean analyst target reflects high expectations for commercial execution, so any launch stumbles could pressure the stock further.
Bull case
- First-in-class and only FDA-approved therapy that inhibits all class I PI3K isoforms and mTOR complexes, with a broad mechanism that may differentiate it from competitors like alpelisib
- Strong early launch indicators: 78% of top 36 strategic accounts placed orders, 91% of US commercial and Medicare lives covered by health plans, per Q3 2026 earnings
- Massive institutional accumulation in Q2 and Q3 2026, with major funds like FMR LLC (Fidelity), Bank of America, Wellington, and Point72 doubling or initiating positions
Bear case
- Stock has fallen sharply from its pre-approval highs: the FDA approval day saw an 11.8% decline, and the stock has continued to slide from ~$103 in July to $66.79 in November 2026, suggesting a 'sell the news' pattern
- No product revenue yet in Q3 2026 (launched Sept 30), with a $73.3 million net loss as the company invests heavily in commercial infrastructure
- Competition from alpelisib (Piqray, Novartis) for PIK3CA mutant patients and from other CDK4/6 inhibitor combinations could limit market share